Last updated 18 days ago

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

10000 patients around the world
Available in Puerto Rico, Brazil, Argentina, Mexico
Eli Lilly and Company
146Research sites
10000Patients around the world

This study is for people with

Obesity

Requirements for the patient

From 45 Years
All Gender

Medical requirements

A body mass index of ≥27.0 kilograms per meter squared (kg/m^2).
Participants may be with or without type 2 diabetes (T2D) unless their hemoglobin A1c (HbA1c) is 10% or lower.
Participants have established atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD), as evidenced at least one of the following:
Coronary artery disease.
Cerebrovascular disease.
Peripheral arterial disease.
Chronic kidney disease defined as:
eGFR <45 millilitres/minute/1.73 meter squared (mL/min/1.73m^2) and UACR >30 milligram/gram (mg/g).
eGFR <60 mL/min/1.73 m^2 and UACR >100 mg/g, or.
eGFR <75 mL/min/1.73 m^2 and UACR >300 mg/g (eGFR is calculated based on Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) cystatin c equation as determined by central lab).
Participants have type 1 diabetes or history of diabetic ketoacidosis.
Participants have any of the following cardiovascular conditions ≤ 90 days prior to randomization:
Myocardial infarction.
Acute coronary syndrome.
Stroke, or.
Coronary, peripheral, or carotid artery arterial revascularization procedure.
Have acute decompensated heart failure requiring hospitalization.
Have New York Heart Association (NYHA) Classification Class IV heart failure at screening.
Participants have an eGFR <20 mL/min/1.73 m^2 at screening.
Have UACR >5000 mg/g at screening.
Have received any form of dialysis ≤ 90 days from the date of randomization.
Have either undergone a kidney transplant or have a transplant procedure scheduled.
Participants have had or plan to have a surgical treatment for obesity.
Have a history of chronic or acute pancreatitis.
Have a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) syndrome type 2.
Have a known clinically significant gastric emptying abnormality, such as severe gastroparesis or gastric outlet obstruction.

Sites

Instituto de Diagnóstico e Investigaciones Metabólicas - IDIM - sede centro - CABA
Instituto de Diagnóstico e Investigaciones Metabólicas - IDIM - sede centro - CABA
Recruiting
Libertad 836 - Libertad 836, Ciudad de Buenos Aires
Instituto de Investigaciones Clínicas Quilmes
Instituto de Investigaciones Clínicas Quilmes
Recruiting
Sarmiento 315, Quilmes, Buenos Aires, Argentina
CEDIMBA - DIM Clínica Privada - Buenos Aires
CEDIMBA - DIM Clínica Privada - Buenos Aires
Recruiting
Belgrano 136, Ramos Mejia, Buenos Aires.
Instituto de Investigaciones Clínicas Córdoba
Instituto de Investigaciones Clínicas Córdoba
Recruiting
Dean Funes 1161, Córdoba
Instituto de Investigaciones Clínicas Tucumán
Instituto de Investigaciones Clínicas Tucumán
Recruiting
Monteagudo 524, San Miguel de Tucumán
Centro Médico Maffei - CABA, Buenos Aires
Centro Médico Maffei - CABA, Buenos Aires
Recruiting
Av. Cerviño 3375, CABA, Buenos Aires
Centro Médico Privado CEMAIC - Córdoba
Centro Médico Privado CEMAIC - Córdoba
Recruiting
Monseñor Pablo Cabrera 2941, Córdoba
Sanatorio Duarte Quiros - Córdoba
Sanatorio Duarte Quiros - Córdoba
Recruiting
Av Duarte Quiros 1948, Córdoba
Centro de Investigaciones Médicas Temperley (CIMeT)
Centro de Investigaciones Médicas Temperley (CIMeT)
Recruiting
Vago 501, Temperley
Centro de Investigaciones Metabólicas (CINME) S.A. - CABA, Buenos Aires
Centro de Investigaciones Metabólicas (CINME) S.A. - CABA, Buenos Aires
Recruiting
Viamonte, Cdad. Autónoma de Buenos Aires, Argentina
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy